Latest News & Features
Big Pharma
NIH rejects petition to use “march-in” rights to allow cheaper competition | Xtandi is “widely available” to public, federal agency says. 23 March 2023
Big Pharma
Hikma label and public statements encouraged infringement, Amarin says | Delaware District Court had dismissed claims label was ‘not skinny enough’. 23 March 2023
Big Pharma
Cipla claims Cabometyx patents are invalid | Exelixis wants generic blocked until at least 2030. 21 March 2023
Biotechnology
New R&D tax incentive announced for SMEs in UK Budget | Funding for medicines regulator aims to open up drug approvals | ‘Hidden benefits’ in Budget for industry | Reaction from Bioindustry Association, Potter Clarkson, Mischon de Reya, Marks & Clerk, Taylor Wessing. 16 March 2023
Medtech
Dispute relates to AstraZeneca ‘Breztri’ brand | Court says no likelihood of confusion with earlier marks | Full details of reasoning. 16 March 2023
Americas
Medtech company wins reversal of earlier ruling | Door opens to mount a challenge of controversial rule | USPTO director‘s updated guidelines influence court’s reasoning. 14 March 2023
Biotechnology
“Customer suit exception” is rejected by district judge | Suit between Chr. Hansen and Glycosyn is ongoing. 14 March 2023
Big Pharma
Sanofi and Regeneron accused of wanting to change patent system | The US Supreme Court will decide whether a controversial court decision should stand. 9 March 2023
Big Pharma
The University of Minnesota had raised three key issues on appeal | Sovereign immunity was at the heart of the years-long dispute. 7 March 2023
Big Pharma
The Roche subsidiary says the licensee owes payments on “stockpile” of MS drug Tysabri. 7 March 2023